Skip to main content
Clinical Trials/NCT02002104
NCT02002104
Completed
N/A

Endothelialized ePTFE Graft by Nanobiotechnology

National Taiwan University Hospital1 site in 1 country6 target enrollmentSeptember 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
The Apparatus for Processing the Tubular Graft Modification Will be Designed and Evaluated.
Sponsor
National Taiwan University Hospital
Enrollment
6
Locations
1
Primary Endpoint
Isolate and expand EPCs from peripheral blood
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The replacement of autologous blood vessels by artificial grafts is urgently needed in clinical applications. Expanded polytetrafluoroethylene (ePTFE) grafts are the most clinically used artificial blood vessels because of its chemical and mechanical stability. But, when used as arteriovenous (AV) grafts for haemodialysis, small diameter ePTFE grafts have a high failure rate of 40% in three years in vivo because of the functional lack of an intact endothelial cell layer. Here we developed a two-step modification including chemical etching and plasma activation to enhance the hydrophilicity of ePTFE. Peptide motifs (eg. cyclic RRE, RGD) known to bind integrins on the endothelial cells were immobilized on ePTFE grafts. Functional peptide immobilization significantly increased the adherence and growth of HUVEC cells on ePTFEs. Patch ePTFE implantation in the pig's descending aorta was used to evaluate the in vivo endothelialization of these modified ePTFE grafts. At 28 days implantation, newly formed endothelial layers on peptide-immobilized ePTFE grafts were demonstrated by SEM and histological analysis. These preliminary data showed the potential to grow an intact endothelial layer to improve the patency rate of the modified ePTFE grafts.

Registry
clinicaltrials.gov
Start Date
September 2010
End Date
June 2011
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Isolate and expand EPCs from peripheral blood

Time Frame: 24 weeks

Obtained from the peripheral blood leukocyte thick liquid (Hsinchu Blood Center, Taiwan Blood Services Fundation)

Study Sites (1)

Loading locations...

Similar Trials